VIM
SUPN icon

VELA Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

VELA Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87M Buy
61,703
+12,408
+25% +$596K 0.63% 56
2026
Q1 		$2.55M Buy
49,295
+1,001
+2% +$51K 0.59% 56
2025
Q4 		$2.4M Buy
48,294
+8,043
+20% +$391K 0.57% 60
2025
Q3 		$1.92M Buy
+40,251
New +$1.62M 0.47% 71

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

VELA Investment Management's SUPN Position: Q2 2026 in Review

VELA Investment Management increased its Supernus Pharmaceuticals (SUPN) stake by 25% in Q2 2026, buying an estimated $596K and bringing the position to 61,703 shares worth $2.87M. The position accounts for 0.63% of the portfolio, ranked #56.

VELA Investment Management first reported a position in SUPN in Q3 2025 and has held it in 4 quarters since. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • VELA Investment Management held 61,703 shares of Supernus Pharmaceuticals worth $2.87M as of Q2 2026.
  • VELA Investment Management bought 12,408 Supernus Pharmaceuticals shares in Q2 2026, an estimated $596K.
  • Supernus Pharmaceuticals made up 0.63% of VELA Investment Management's portfolio in Q2 2026, its #56 holding.
  • VELA Investment Management first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on VELA Investment Management's 13F filing for Q2 2026, filed 3 Aug 2026.